10-Q quarterly report · filed Nov 6, 2026

CG Oncology, Inc. (CGON) Q3 2026 10-Q Quarterly Report

Short answer

CG Oncology, Inc. (CGON) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2M (down 3.7% year over year) with net income of −$57M.

Q3 2026 key financials · XBRL

Revenue
$2M
−3.7% YoY · +38.6% QoQ
Net income
−$57M
−29.9% YoY · +28.0% QoQ
Operating margin
-3943.2%
EPS (diluted)
−$0.64
−12.3% YoY · +28.9% QoQ

Source: XBRL data from the CG Oncology, Inc. (CGON) Q3 2026 10-Q on SEC EDGAR. USD.

CG Oncology, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $1.604M, down $0.062M YoY from $1.666M
  • Net loss $56.891M vs $43.808M YoY, operating loss $63.249M vs $51.129M
  • Commercial and development revenue $1.604M vs $1.508M, strongest line; license revenue $0 vs $0.158M
  • Operating cash use $151.064M through nine months, cash and securities $984.5M
  • BLA submission expected in fourth quarter 2026, funding projected for at least twelve months

Risk Factors

  • No material changes to previously disclosed risk factors in the 2025 Annual Report
  • Regulatory risk: Continued SEC compliance exposure under previously disclosed risks
  • Clinical development risk: Product candidates may fail trials or regulatory approval
  • Liquidity risk: Future capital needs may require additional financing
  • Commercial risk: Competition could limit product adoption and market opportunity

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CG Oncology, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.